Camptothecin analogs with enhanced activity against human breast cancer cells. I. Correlation of potency with lipophilicity and persistence in the cleavage complex David J. AdamsMateus Webba da SilvaMansukh C. Wani Original Article 23 August 2005 Pages: 135 - 144
Camptothecin analogs with enhanced activity against human breast cancer cells. II. Impact of the tumor pH gradient David J. AdamsMiriam L. WahlMansukh C. Wani Original Article 05 July 2005 Pages: 145 - 154
Pharmacodynamic effects of high dose lovastatin in subjects with advanced malignancies Sarah A. HolsteinHoward R. KnappRaymond J. Hohl Original Article 30 August 2005 Pages: 155 - 164
4-methylumbelliferone, a hyaluronan synthase suppressor, enhances the anticancer activity of gemcitabine in human pancreatic cancer cells Hideaki NakazawaShuichi YoshiharaMutsuo Sasaki Original Article 15 September 2005 Pages: 165 - 170
Low folate conditions may enhance the interaction of trifluorothymidine with antifolates in colon cancer cells Olaf H. TemminkMarco F. M. HoogelandGodefridus J. Peters Original Article 12 July 2005 Pages: 171 - 179
Thiolo-, thiono- and dithiocarbonate and thiocarbamate derivatives of demethylpenclomedine as novel anticancer agents Robert F. StruckWilliam R. Waud Original Article 11 August 2005 Pages: 180 - 184
Gemcitabine plus celecoxib (GECO) in advanced pancreatic cancer: a phase II trial Vittorio FerrariFrancesca ValcamonicoGiovanni Marini Original Article 03 September 2005 Pages: 185 - 190
Intravenous busulfan in adults prior to haematopoietic stem cell transplantation: a population pharmacokinetic study L. NguyenF. LegerC. Puozzo Original Article 25 August 2005 Pages: 191 - 198
Pharmacokinetics, pharmacodynamics and adherence to oral topotecan in myelodysplastic syndromes: a Cancer and Leukemia Group B study Cheri E. KleinHelen KastrissiosMark J. Ratain Original Article 13 September 2005 Pages: 199 - 206
Combination of topotecan and cisplatin in relapsed patients with small cell lung cancer: a phase II study of the hellenic cooperative oncology group (HeCOG) Christos ChristodoulouHaralambos P. KalofonosEpaminondas Samantas Original Article 19 July 2005 Pages: 207 - 212
Dihydroartemisinin downregulates vascular endothelial growth factor expression and induces apoptosis in chronic myeloid leukemia K562 cells Jun LeeHui-Jun ZhouXiu-Hua Wu Original Article 02 August 2005 Pages: 213 - 220
Structure-activity study of the interaction of bioreductive benzoquinone alkylating agents with DNA topoisomerase II Brian B. HasinoffXing WuJack C. Yalowich Original Article 12 July 2005 Pages: 221 - 233
Expression of VDR and CYP24A1 mRNA in human tumors Mark G. AndersonMasaki NakaneJ. Ruth Wu-Wong Original Article 23 September 2005 Pages: 234 - 240
Prospective evaluation of carboplatin AUC dosing in patients with a BMI ≥27 or Cachexia Jon D. HerringtonHai T. TranMark W. Riggs Original Article 25 August 2005 Pages: 241 - 247
Experimental study of the inhibition of human hepatocarcinoma Bel7402 cells by the tripeptide tyroserleutide(YSL) Rong LuJing JiaZhi Yao Original Article 19 July 2005 Pages: 248 - 256
Analysis of cytotoxicities of platinum compounds Jerry GoodismanDouglas HagrmanAbdul-Kader Souid Original Article 19 July 2005 Pages: 257 - 267
Antiproliferative activity of contragestazol (DL111-IT) in murine and human tumor models in vitro and in vivo Bo YangQiao-jun HeRui-ying Fang Original Article 23 August 2005 Pages: 268 - 273
